FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
August 03, 2015
from PR Newswire
Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development
July 15, 2015
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
June 29, 2015
Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders
May 15, 2015
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program
May 11, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here